Background: The purpose of this study was to investigate the prognostic significance of serum sCD163 in patients with epithelial ovarian cancer.
Methods: Preoperative serum samples from 55 patients with epithelial ovarian cancers were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay kit. A Cox proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for disease-free survival (DFS) and overall survival (OS).
Results: Median serum sCD163 levels were higher in patients with a high-grade tumor. High serum sCD163 levels (3.43 mg/l) were associated with poor prognostic factors such as advanced stage (p = 0.024) and positive peritoneal cytology (p = 0.015). Univariate survival analysis showed that elevated sCD163 levels were associated with short DFS (8.0 vs. 32.4 months, p = 0.04) and OS (19.7 vs. 40.0 months, p = 0.027). Multivariate survival analysis revealed that high serum sCD163 levels were negatively associated with DFS (HR 3.1, 95% CI 1.2-8.1, p = 0.039).
Conclusions: Our study shows that elevated serum sCD163 levels were associated with poor prognosis in patients with ovarian cancer.
Impact: The prognostic significance of serum sCD163 in patients with epithelial ovarian cancer is described.
Copyright © 2013 S. Karger AG, Basel.